Asfotase alfa therapy for children with hypophosphatasia by Whyte, Michael P et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
6-16-2016 
Asfotase alfa therapy for children with hypophosphatasia 
Michael P. Whyte 
Katherine L. Madson 
Dawn Phillips 
Amy L. Reeves 
William H. McAlister 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Michael P. Whyte, Katherine L. Madson, Dawn Phillips, Amy L. Reeves, William H. McAlister, Amy 
Yakimoski, Karen E. Mack, Kim Hamilton, Kori Kagan, Kenji P. Fujita, David D. Thompson, Scott Moseley, 
Tatjana Odrljin, and Cheryl Rockman-Greenberg 
Asfotase alfa therapy for children with hypophosphatasia
Michael P. Whyte, … , Tatjana Odrljin, Cheryl Rockman-Greenberg
JCI Insight. 2016;1(9):e85971. https://doi.org/10.1172/jci.insight.85971.
 
Background. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-
nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP
phosphohydrolase activity leads to extracellular accumulation of inorganic pyrophosphate, a natural substrate of TNSALP
and inhibitor of mineralization. Children with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle
weakness, and premature deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected
s.c. to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening perinatal and
infantile forms of HPP.
Methods. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to children 6–12 years of
age at baseline who were substantially impaired by HPP. Two radiographic scales quantitated HPP skeletal disease,
including comparisons to serial radiographs from similarly affected historical control patients.
Results. Twelve children receiving treatment were studied for 5 years. The 6-month primary endpoint was met, showing
significant radiographic improvement. Additional significant improvements included patient growth, strength, motor
function, agility, and quality of life, which for most patients meant achieving normal values for age- and sex-matched peers
that were sustained at 5 […]
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Introduction
Hypophosphatasia is the inborn error of  metabolism caused by loss-of-function mutation(s) of  the gene 
that encodes the tissue-nonspecific isoenzyme of  alkaline phosphatase (TNSALP) (1, 2). TNSALP is a cell-
surface phosphohydrolase richly expressed in bone, liver, and kidney (3), and deficient TNSALP activity in 
hypophosphatasia leads to extracellular accumulation of  its natural substrates, including inorganic pyro-
phosphate (PPi) (4) and pyridoxal 5′-phosphate (PLP) (5). PPi is a potent inhibitor of  mineralization (6), 
BACKGROUND. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene 
that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, 
cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of 
inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children 
with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature 
deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s.c. 
to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening 
perinatal and infantile forms of HPP.
METHODS. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to 
children 6–12 years of age at baseline who were substantially impaired by HPP. Two radiographic 
scales quantitated HPP skeletal disease, including comparisons to serial radiographs from similarly 
affected historical control patients.
RESULTS. Twelve children receiving treatment were studied for 5 years. The 6-month primary 
endpoint was met, showing significant radiographic improvement. Additional significant 
improvements included patient growth, strength, motor function, agility, and quality of life, 
which for most patients meant achieving normal values for age- and sex-matched peers that 
were sustained at 5 years of treatment. For most, pain and disability resolved. Mild to moderate 
injection-site reactions were common and were sometimes associated with lipohypertrophy. Low 
anti–asfotase alfa antibody titers were noted in all patients. No evidence emerged for clinically 
important ectopic calcification or treatment resistance.
CONCLUSIONS. Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy 
with a good safety profile for children suffering from HPP.
TRIAL REGISTRATION. ClinicalTrials.gov NCT00952484 (https://clinicaltrials.gov/ct2/show/
NCT00952484) and NCT01203826 (https://clinicaltrials.gov/ct2/show/NCT01203826).
FUNDING. Alexion Pharmaceuticals Inc. and Shriners Hospitals for Children.
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and the excessive PPi in hypophosphatasia can block hydroxyapatite crystal formation within the skeletal 
matrix (7, 8), causing rickets during growth (9) or osteomalacia in adult life (10). Impaired hydrolysis of  
PLP in severely affected babies can lead to neurotransmitter deficiency and vitamin B6–dependent seizures 
(11). The clinical expressivity of  hypophosphatasia is classified according to whether there are dental com-
plications alone (odontohypophosphatasia) or to patient age when skeletal and other problems first mani-
fest (1, 2, 12). Perinatal hypophosphatasia is almost always fatal soon after birth (13), and infantile hypoph-
osphatasia has a mortality estimate of  50% during the first year of  life (1, 2). Childhood hypophosphatasia 
features rickets often complicated by skeletal pain, fracturing, muscle weakness, abnormal ambulation or 
gait, and premature loss of  deciduous teeth (1, 2, 14).
Asfotase alfa is a recombinant, bone-targeted, human TNSALP developed to treat hypophosphatasia 
(15). In 2012, we reported that infants and young children (≤3 years of  age) with life-threatening perinatal 
and infantile hypophosphatasia showed substantial radiographic healing of  rickets, improved respiratory 
status, and better physical function during 1 year of  asfotase alfa treatment (9). Here, we assess the impact 
of  5 years of  asfotase alfa treatment in a separate cohort of  older children (6–12 years of  age) with either 
infantile- or childhood-onset disease who were substantially impaired by hypophosphatasia, including 
effects on their skeletal manifestations, growth, physical function, and quality of  life.
Results
Patient Characteristics. Thirteen children — 11 boys and 2 girls with infantile hypophosphatasia or compro-
mised by childhood hypophosphatasia (16) — were enrolled between September 2009 and January 2010 
for treatment (Figure 1). Their case summaries are detailed in the Supplement; supplemental material avail-
able online with this article; doi:10.1172/jci.insight.85971DS1. Enrollment ages ranged from 6–12 years 
(Table 1). Reported skeletal abnormalities included knock knees (77%), rachitic chest (46%), bowing of  
leg(s) (39%), and craniosynostosis (31%) and were accompanied by muscle weakness in most patients and 
an unusual gait in all. Bone pain often limited activities (46%) and/or required analgesics (39%). Nearly 
half  the patients had poor weight gain and prior difficulty feeding. Hypercalcemia had occurred in 31%. 
After 1 month of  treatment, 1 boy withdrew for elective scoliosis surgery. Figure 2 is an example of  the 
radiographic abnormalities that can be observed in a child with untreated hypophosphatasia.
The 16 historical controls — 11 boys and 5 girls with infantile or childhood hypophosphatasia — 
Figure 1. Study design and patient participation. During the 6-month initial phase involving 13 participants, 1 child withdrew for elective surgery after 
1 month of treatment. The remaining 12 were assessed up to 5 years (60 months) of treatment and continue on study. Data were pooled across these 2 
phases for analysis. The radiographic findings were contrasted to 2-year experience with 16 historical control patients. *ClinicalTrials.gov: NCT00952484, 
NCT01203826. LOCF, last observation carried forward.
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were slightly younger compared with the treatment group when their first study-eligible radiographs 
had been taken, and they had a lower median serum ALP level than the treatment group. All other 
assessed characteristics, including their medical histories and demographic findings, were similar to the 
treatment group (Table 1).
Primary endpoint: skeletal radiographic changes. After 6 weeks of  asfotase alfa administered s.c., the medi-
an Radiographic Global Impression of  Change (RGI-C) score (see Methods) had improved significantly 
(+1.0 [0.0, +2.0; min, max]; P = 0.001). Except where noted, values are expressed as median (min, max). 
Table 1. Patient demographic and baseline characteristics
Historical Control Patients Treated Patients
n 16 13
Age (yrs) at enrollment
Mean ± SD 6.0 ± 1.8 8.8 ± 2.2
Median (min, max) 5.5 (4, 11) 8.6 (6, 12)
Sex, % (n)
Male 69% (11) 85% (11)
Ethnicity, % (n)
Not Hispanic or Latino NA 92% (12)
Race, % (n)
White NA 92% (12)
Form of hypophosphatasia, % (n)
Infantile 44% (7) 38% (5)
Childhood (≥6 mos to <18 yrs) 56% (9) 62% (8)
Age (mos) at onset of hypophosphatasia symptoms
Mean ± SD 7.4 ± 9.5 10.5 ± 7.0
Median (min, max) 6.0 (0, 40) 12.0 (1, 22)
Baseline RSS (0 = normal, 10 = severe)
Mean ± SD 1.44 ± 0.96 2.77 ± 1.33
Median (min, max) 1.0 (0.0, 3.5) 3.0 (0.5, 6.0)
Baseline plasma PPi (μM)
Mean ± SD NA 5.01 ± 0.97
Median (min, max [normal range]) 4.86 (3.74, 6.96 [0.75–5.71 µM])
Baseline serum PLP (ng/ml)
Mean ± SD 323 ± 178 214 ± 127
Median (min, max [normal range]) 328 (85, 726 [5.7–61.2 ng/ml]) 218 (76, 527 [5.7–61.2 ng/ml])
Baseline serum calcium (mmol/l)
Mean ± SD 2.5 ± 0.10 2.5 ± 0.10
Median (min, max [normal range]) 2.52 (2.35, 2.78 [2.12–2.57 mmol/l]) 2.50 (2.37, 2.67 [2.12–2.57 mmol/l])
Hypophosphatasia-related disease history, % (n)
Unusual gait or running NA 100% (13)
Premature tooth loss 100% (13)
Delayed (≥15 mos) walking 85% (11)
Knock knees 77% (10)
Muscle weakness 62% (8)
Elevated serum phosphorous 54% (7)
Difficulty eating/swallowing 46% (6)
Difficulty gaining weight 46% (6)
Hypermobility 46% (6)
Joint pain 46% (6)
Muscle pain 46% (6)
Abnormally shaped chest 46% (6)
Bone pain severe enough to limit activities 46% (6)
Bone pain severe enough to require medication 39% (5)
Bowing of legs 39% (5)
NA, not available; PLP, pyridoxal-5′ phosphate; PPi, inorganic pyrophosphate; RSS, Rickets Severity Score.
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Further improvement occurred by 6 months (Figure 3) 
and persisted through 5 years (+2.2 [+1.7, +2.7]; 
P = 0.0005) (see Supplement). For no patient did 
the score worsen. However, at 5 years of  treatment, 
the median score had not reached +3 for complete 
or nearly complete healing of  all treated patients. In 
contrast, no significant change occurred in the RGI-C 
score of  the historical controls spanning up to 2 years 
(Figure 3). The RGI-C responder analysis showed 
69% (9/13) of  treated patients achieved “respond-
er” designation (RGI-C score ≥ +2) at 6 months of  
therapy (last observation carried forward [LOCF] 
data imputation applied) compared with 6% (1/16) 
of  the historical controls (P = 0.007). The percentage 
of  treated patients considered responders then further 
improved steadily; 75% at 2 years, 88% at 3 years, and 
92% at 5 years (1 patient had withdrawn at month 1). 
Representative radiographs are illustrated in Figure 
4. Consistent with the RGI-C findings, the Rickets 
Severity Score (RSS; see Methods) analysis confirmed 
improvement of  rickets with treatment (documenting 
significantly decreased median RSS scores comparing 
the first eligible radiographs with all subsequent evalu-
ated time points) as contrasted to the historical controls (Supplemental Table 1).
TNSALP replacement and substrates. Twelve of  the 13 treated patients had at least 1 mutant TNSALP allele 
identified using PCR and DNA sequencing of  all coding exons and splice sites (Supplemental Table 2). 
The exception (patient 11) has not shown a TNSALP gene mutation despite extensive molecular investi-
gations. The median serum ALP activity of  the treatment group at baseline was 49 IU/l (min, max: 27, 
68; see Supplement for age- and sex-specific normal ranges for each patient) and then rapidly increased, 
presumably reflecting asfotase alfa activity, with treatment. At 5 years of  therapy, it remained markedly ele-
vated at 5747 IU/l (3,039, 9,959). Baseline plasma PPi median concentration, 4.9 μM (3.7, 7.0), was near 
the upper limit of  the age-dependent reference range (0.75–5.71 μM). Baseline plasma PLP median concen-
tration, 218 ng/ml (76, 527), was clearly elevated (normal 5.7–61.2 ng/ml). At 6 weeks of  treatment, rapid 
and significant reduction of  plasma PPi and PLP concentrations had achieved the normal limits for most 
treated patients (2.0 μM [1.3, 3.1] and 10.6 ng/ml [0.9, 40.3], respectively). Then, normal levels generally 
persisted throughout the study (Supplemental Figure 1).
Growth. With treatment, the first significant increase in the group’s weight Z scores (Figure 5A) was 
identified at 6 weeks (baseline: –1.21 [–8.2, 2.3]; 6 weeks: –0.92 [–8.0, 2.1], P = 0.0048), and the first signifi-
cant increase in the group’s height Z scores was noted after 1.5 years (baseline: –1.26 [–6.6, 0.0]; 1.5 years: 
–0.87 [–6.6, –0.3], P = 0.0257) (Figure 5B). BMI was increased at 5 years of  treatment (baseline: –0.57 
[–1.4, 2.4]; 5 years: 0.05 [–1.0, 2.2], P = 0.0077) (Figure 5C).
Strength. Most treated patients became stronger for their age and sex; e.g., right hip abduction base-
line median at 13.6 lbs was 7.3 and 22.1 (min, max, respectively; 50% predicted for healthy peers). At 6 
months, 18.3 lbs, minimum and maximum values were 8.4 and 28.2, respectively (P = 0.0018 or 60% pre-
dicted). At 5 years, 30.7 lbs, minimum and maximum values were 19.5 and 84.4, respectively (P = 0.0079 
Figure 2. Skeletal features of untreated hypophosphatasia. 
Untreated, the radiographic features of hypophosphatasia 
in children (e.g., patient 7) include, as in the wrist pictured, 
osteopenia, metaphyseal fraying, metaphyseal flaring, 
and metadiaphyseal sclerosis, and as in the knee pictured, 
characteristic “tongues” of radiolucency, irregularity of 
the provisional zone of calcification, distal metaphyseal 
demineralization, transverse subphyseal band of lucency, 
and apparent physeal widening.
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or 91% predicted). Significant improvements were similarly documented for hip and knee extensors and 
knee flexors (Supplemental Figure 2).
Physical function. Before treatment, gross motor delays and functional disability were documented in 
most patients; e.g., 9 of  the 13 had a subnormal (<80% predicted) 6-minute walk test (6MWT). After 5 
years of  treatment, 7 of  these 9 children achieved or surpassed 80% of  the predicted distance (± 2 SD 
mean), indicating normal ambulation. The median score increased from 61% at baseline to 83% at 5 years 
(P = 0.0002; Figure 6A; Video 1; Supplemental Figure 3).
The median value for the Bruininks-Oseretsky Test of  Motor Proficiency, Second Edition (BOT-2) 
Strength and Agility Composite Score at baseline (28.0 [20.0, 37.0]; percentile rank = 1.0) was greater than 
2 SD below the median score of  50 for healthy, age-matched peers (17). During treatment, it improved, 
reaching the normal range after 1 year, and was significantly better after 5 years (46.0 [33.0, 64.0]; P ≤ 
0.0001; percentile rank = 35.0) (Figure 6B; Video 2; Supplemental Figure 4). The magnitude of  change in 
the standard scores indicated gross motor function within the normal range (± 1 SD mean).
Pain and disability assessments. Improvements in the above effort-dependent functional tests were sub-
stantiated by the parent-reported Child Health Assessment Questionnaire (CHAQ) and Pediatric Outcomes 
Data Collection Instrument (PODCI) results. These clinically meaningful advances persisted through 5 
years. The elevated CHAQ pain (20.0 [0.0, 72.0]) and disability (1.0 [0.0, 2.3]) medians at baseline were 0 
at 5 years of  treatment, indicating no pain or disability for most patients (0.0 [0.0, 60.0], P = 0.1125; 0.0 
[0.0, 1.0], P = 0.0002, respectively) (Figure 6C). The PODCI global function median score, which was 
abnormal at baseline (27.0 [–2.0, 55.0]), improved to slightly above normal at the 5-year assessment (52.0 
[28.0, 57.0], P = 0.0002).
Safety. There were no deaths, serious adverse events (AEs), or withdrawals due to AEs. One patient 
receiving asfotase alfa 9 mg/kg/week s.c. underwent dose reduction for a low plasma PLP level. Four 
patients had injection-associated reactions (IARs) (10 events) during the first month of  treatment. All were 
Figure 3. Skeletal improvements during treatment with asfotase alfa. Changes in RGI-C scores during 6 months and 
2 years of treatment with asfotase alfa. Individual dots illustrate the distribution of individual patient scores at each 
time point. Boxes represent the median RGI-C scores and represent first and third quartiles. Whisker lines above and 
below the boxes represent the end-range of patient scores. The RGI-C is scored on a scale ranging from –3 to +3, with 
0 representing no change. Negative values represent worsening, and positive values represent improvement or heal-
ing. A score of +3 indicates nearly complete or complete healing. Median RGI-C scores for the historical controls and 
asfotase alfa were 0 and 2, respectively, at 6 months and 2 years. The number of patients assessed at each time point 
is shown below each bar. P ≤ 0.0001 by Wilcoxon signed-rank test at all time points compared with no change.
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injection-site reactions (ISRs), with the exception of  nausea and peripheral edema in 1 patient, and all 
were assessed by the investigators as mild. Each patient experienced at least 1 treatment-emergent AE; 86% 
mild and 14% moderate in severity. Most AEs (53%) were considered by the investigators to be unrelated 
to the treatment. When we excluded the ISRs, 2% of  AEs were deemed treatment related. The most com-
mon therapy-related AEs were ISRs that were typically mild (Table 2 and Supplemental Figure 5A). For 8 
patients, 26 events were considered focal lipohypertrophy, of  which 8 were moderate in severity (Supple-
mental Figure 5B); the others were mild at data cutoff, and no dose adjustments were made. The lipohyper-
trophy occurred for 6 patients receiving 6 injections weekly and 2 patients receiving 3 injections weekly, all 
receiving the same weekly dose (mg/kg) of  asfotase alfa. At 3 years of  treatment and thereafter, localized 
lipohypertrophy persisted in 6 of  the 8 patients. The dose of  asfotase alfa was reduced for 1 patient with 
mild ISRs (multiple macules). To minimize ISRs, injection-site rotation was emphasized for all patients.
Surveillance of the patients’ radiographs showed no evidence of ectopic calcification. On ophthalmoscopy, 
the retinal examinations were consistently unremarkable. However, 46% (6 of 13) of the patients showed small 
refractile deposits in the conjunctiva or cornea presumed to contain calcium. For 5 patients, these were consid-
ered possibly or probably related to the treatment. No deposit was deemed clinically apparent or significant. 
No patient developed nephrocalcinosis, although after approximately 2 years of treatment, renal sonography 
revealed “focal echogenicity” consistent with a small renal stone present for 6 months in 1 kidney of 1 patient.
All 12 patients tested would show anti–asfotase alfa antibodies. Five of  the 6 patients who began treat-
ment in the 3 mg/kg dose group were antibody positive by Week 6, and all were antibody positive at Week 
12 of  treatment. In those starting in the 2 mg/kg dose group, 1 patient was antibody positive by Week 6, 
and 5 patients were positive by Week 48. In 5 of  the 12 patients, the antibodies were neutralizing in vitro at 
1 or more time points, but with no apparent compromise of  therapeutic efficacy.
Figure 4. Representative radiographic changes. Radiographic changes were documented in 12 treated patients and are illustrated in the Supplemental 
Methods. Patient 7, a 6-year-old boy at enrollment, is shown. RGI-C, Radiographic Global Impression of Change; RSS, Rickets Severity Score. Note the 
improvements at 6 months of treatment that persist after 5 years of therapy.
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Discussion
Hypophosphatasia features the greatest range of  severity of  all skeletal diseases (1) and represents the last 
rickets or osteomalacia to have a medical treatment (2, 18). Asfotase alfa is a first-in-class, bone-targeted, 
enzyme replacement therapy for hypophosphatasia (2).
In this study, asfotase alfa was administered for the first time to older children (6–12 years old) impaired 
by the infantile and childhood forms of  hypophosphatasia, all of  whom had skeletal involvement, muscle 
weakness, and/or difficulties with ambulation. Due to the rarity of  hypophosphatasia (1), a concurrent 
control group was not possible, but evaluation of  the primary outcome objective (12) concerning the radio-
graphic changes of  this disorder was improved using radiographs from a pediatric historical control group, 
also with infantile or childhood hypophosphatasia, assessed concomitantly by the same radiologists.
Skeletal improvement with asfotase alfa therapy was verified using 2 scales to study (9) the sequential 
radiographs of  the 12 treated patients and the 16 age- and sex-matched historical control patients. Both 
scales documented no change in the controls but instead documented substantial healing of  the skeletal 
disease after 6 months of  treatment that persisted through the 5 years of  therapy. Skeletal healing did not 
become complete for all patients.
As the weakness improved and the skeleton mended, there was substantially better physical function, 
including walking distance, and most patients showed improved growth. Gross motor function, strength for 
all proximal muscles tested, agility, and stamina typically achieved their normal ranges and together were 
the basis for independent and age-appropriate performance of  daily living activities. For most patients, their 
pain and disability resolved. Consistent with the radiographic findings, the treated patients demonstrated 
better skeletal mineralization assessed as bone mineral density quantitated by dual-energy x-ray absorpti-
ometry and histomorphometry of  transiliac crest bone biopsies (data not shown). Low titers of  anti–asfo-
tase alfa antibodies were found in all patients tested, but there was no evidence of  resistance to this biologic.
Although the pathogenesis of  the muscle weakness of  hypophosphatasia is not understood (1, 2), 
it can be an important complication. Notably, the muscle weakness, hyperphosphatemia, and rickets 
or osteomalacia characteristic of  hypophosphatasia (1, 2) are hallmarks of  toxicity from the first-gen-
eration bisphosphonate, etidronate, a synthetic analog of  PPi (19). Perhaps the high extracellular lev-
els of  PPi in hypophosphatasia somehow compromise muscle function and are corrected by asfotase 
alfa treatment.
No deaths or safety-related discontinuation of  therapy occurred during this study. Asfotase alfa treat-
ment was generally well tolerated and safe. Although it markedly increased circulating ALP activity, no 
clinically important ectopic mineralization occurred. Possibly, avoidance of  ectopic calcification in our 
treated patients reflected reduction of  extracellular PPi levels into the normal range but not overcorrection 
(i.e., suppression) (19). The most common AEs were mild to moderate ISRs. Lipohypertrophy appeared in 
some children, but its pathogenesis is unknown.
Table 2. Injection-site reactions
Asfotase Alfa (n = 13)
System Organ Class Preferred Term Events Patients, n (%)
Total 250 12 (92)
Erythema 71 11 (85)
Hypertrophy 26 8 (62)
Pruritus 23 7 (54)
Pain 18 6 (46)
Atrophy 13 5 (38)
Discoloration 17 5 (38)
Swelling 12 3 (23)
Induration 1 1 (8)
Nodule 1 1 (8)
Papule 1 1 (8)
Urticaria 1 1 (8)
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In conclusion, asfotase alfa treat-
ment has substantial efficacy for chil-
dren impaired by hypophosphatasia. 
Better stature and improved strength 
and agility accompanied significant 
healing of  the skeletal manifestations 
and persisted through 5 years of  treat-
ment. The treatment was well tolerated 
and seemed safe, with a favorable ben-
efit-risk profile. In 2015, asfotase alfa 
became the only approved medical 
therapy for hypophosphatasia in Japan 
and the only approved medical therapy 
for pediatric-onset hypophosphatasia 
in Canada, the European Union, and 
the United States.
Methods
Study design. This open-label study 
(NCT00952484 and NCT01203826) 
sponsored by Alexion Pharmaceuti-
cals Inc. evaluated the efficacy, safety, 
tolerability, and pharmacokinetics of  
asfotase alfa given to children com-
promised by hypophosphatasia. The 
study began as a 6-month assessment 
of  6- to 12-year-old, Tanner stage 
≤2 survivors of  infantile hypophos-
phatasia or patients with childhood 
hypophosphatasia (16). Those who 
completed this initial study entered an 
extension phase (Figure 1). Our report 
summarizes the findings during their 
first 5 years of  treatment. The data 
cutoff  was November 5, 2014; the 
study is ongoing.
Inclusion criteria required radio-
graphic skeletal features of  hypophos-
phatasia-related rickets, serum ALP 
activity below age-adjusted lower lim-
its of  normal, and plasma PLP levels 
at least twice the upper limit of  nor-
mal. Serum 25-hydroxyvitamin D had 
to be greater than or equal to 20 ng/ml 
(50 nM). Exclusion criteria included 
treatable rickets, hypocalcemia, hypo-
Figure 5. Growth during treatment with 
asfotase alfa. Growth was assessed by Z 
scores for (A) weight, (B) height, and (C) 
BMI. For all graphs, individual dots indicate 
individual patient scores at each time 
point. Median, min, max, and n values are 
given below each panel. P values at 5 years 
from Wilcoxon signed-rank test.
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phosphatemia, or bisphosphonate 
exposure (see Supplemental Meth-
ods). Radiographic skeletal changes 
during the first 2 years of  asfotase alfa 
treatment were compared with simi-
lar but untreated pediatric historical 
controls with hypophosphatasia who 
had been studied at Shriners Hospital 
for Children but were too old for the 
treatment study or declined participa-
tion. Their bilateral wrist and/or knee 
radiographs, previously obtained at 
intervals spanning 6 months to 2 years 
between 5 and 12 years of  age, were 
evaluated as close to 6 months or 1–2 
years apart for comparison with the 
treatment group.
Asfotase alfa was provided by 
the sponsor, Alexion Pharmaceu-
ticals Inc. Patients to receive s.c. 
injections of  asfotase alfa (40 or 100 
mg/ml concentration) were initially 
randomized to 2 or 3 mg/kg thrice 
weekly (i.e., 6 or 9 mg/kg/week) for 
6 months (Figure 1). In the exten-
sion study, patients initially received 
3 mg/kg/week either as 0.5 mg/kg 6 
times weekly or 1 mg/kg thrice week-
ly until preliminary analysis led to a 
protocol amendment that doubled 
the dose to 6 mg/kg/week to maintain therapeutic efficacy. Doses could be adjusted by the investigator 
together with the sponsor for safety concerns (any time) or lack of  efficacy (extension phase only). Since 
a separately identified historical control patient group was used for comparison, there was no random-
ization between the drug-treated and control patients.
Figure 6. Functional assessment during 
treatment with asfotase alfa. (A) Percent 
predicted 6MWT distance median achieves 
the normal range after 6 months of 
treatment and is sustained at 5 years of 
therapy. P ≤ 0.0005 by paired t test for the 
mean difference between each time point 
and baseline. (B) Gross motor function, 
assessed using the BOT-2 Running Speed 
and Agility subtest (17), shows median 
scores reaching the normal range (gray 
area) by 1 year of treatment that were 
sustained. Median, min, max, and n values 
are given within the figure. (C) Disability 
assessment using the CHAQ (24) shows 
patient improvement. *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001 mean difference for 
each time point compared with baseline 
by paired t test. Median, min, max, and n 
values are given below each figure. For all 
graphs, individual dots indicate individual 
patient scores at each time point. Gray 
area represents the normal range.
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Outcome assessments. The primary endpoint objective, evaluation of  changes in the skeletal manifesta-
tions of  hypophosphatasia (see Supplemental Methods), was obtained using the RGI-C (9) and RSS (20). 
The RGI-C, a 7-point ordinal scale, assesses hypophosphatasia skeletal disease in wrists and knees, includ-
ing physeal widening, irregularity of  the provisional zone of  calcification, metaphyseal flaring, radiolucen-
cies, and patchy osteosclerosis, as well as recent fractures (see Supplemental Methods) (9). The changes 
compared with baseline were quantified independently by 3 pediatric radiologists blinded to treatment time 
points and group assignments. For the RGI-C, +3 signifies complete or nearly complete healing, whereas 
–3 represents severe worsening. The scores per patient were averaged across radiologists at each time point. 
An RGI-C “responder” had a score greater than or equal to +2 (i.e., substantial or near/complete healing) 
(9). The RSS, which was developed to assess nutritional rickets, was scored by the same individual rater to: 
(i) evaluate the treated patients’ radiographs throughout the study and (ii) evaluate the historical control 
radiographs representing 6-month, 1-year, and 2-year intervals. Knee and wrist growth-plate abnormalities 
and metaphyseal fraying and cupping were rated according to a 10-point scale (0 = no rickets; 10 = severe 
rickets), with scores for each radiograph determined in random order (Supplemental Table 3) (20).
Secondary endpoint assessments included changes in TNSALP substrate levels (i.e., plasma PPi and 
PLP); growth (i.e., height, weight, and BMI Z scores); strength of  muscle groups that move the hips and 
knees, measured using a hand-held dynamometer (21); walking ability and endurance/speed, using a 
6MWT (22); physical function and strength by BOT-2 (17); global function, including pain and interference 
with normal activities, by the PODCI (23); and disability by the CHAQ (24) (Supplemental Methods). Nor-
mative PODCI scores for a healthy population have a mean of  50 with standard deviation of  10 and range 
from –77 (worst) to +58 (best). The CHAQ disability scores range from 0–3, with higher scores indicating 
greater disability.
Safety and tolerability primary endpoint surveillance included evaluation of  AEs, deaths, vital signs, 
physical examination, laboratory testing (standard biochemistry, hematology, and urinalysis; Covance 
Inc.), ophthalmologic examination for ectopic calcification (during the extension phase), renal ultrasound 
for nephrocalcinosis, and anti–asfotase alfa antibody formation.
Statistics. Data management and statistical analyses (SAS Version 9.2, SAS Institute Inc.) were per-
formed by the sponsor. Except where noted, values are expressed as median (min, max). The RGI-C 
median scores were compared using Wilcoxon rank-sum test. Missing values were imputed with LOCF, 
and patients with no postbaseline assessment were assigned “no change” (e.g., RGI-C = 0). Observed 
median and mean within-group changes were also assessed for difference from 0 using the Wilcoxon 
signed-rank test and paired t test. All analyses were 2-sided, with significance defined as P less than 0.05. 
Otherwise, descriptive statistics are reported.
Study approval. Safety and efficacy surveillance included an independent monitoring board. The study 
was designed by the authors and sponsor. The protocol, its amendments, and informed consent/assent doc-
uments were approved by the governing IRBs for Shriners Hospital for Children and for the University of  
Manitoba. Written informed consent was obtained from the parent(s) or legal guardian(s) and assent from 
the study patients. All authors affirm data completeness and accuracy and protocol adherence.
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